Subgroups of older adults with osteoarthritis based upon differing comorbid symptom presentations and potential underlying pain mechanisms by Murphy, Susan L et al.
RESEARCH ARTICLE Open Access
Subgroups of older adults with osteoarthritis based
upon differing comorbid symptom presentations
and potential underlying pain mechanisms
Susan L Murphy1,2*, Angela K Lyden1, Kristine Phillips3, Daniel J Clauw3,4 and David A Williams3,4,5
Abstract
Introduction: Although people with knee and hip osteoarthritis (OA) seek treatment because of pain, many of
these individuals have commonly co-occurring symptoms (for example, fatigue, sleep problems, mood disorders).
The purpose of this study was to characterize adults with OA by identifying subgroups with the above comorbid
symptoms along with illness burden (a composite measure of somatic symptoms) to begin to examine whether
subsets may have differing underlying pain mechanisms.
Methods: Community-living older adults with symptomatic knee and hip OA (n = 129) participated (68% with
knee OA, 38% with hip OA). Hierarchical agglomerative cluster analysis was used. To determine the relative
contribution of each variable in a cluster, multivariate analysis of variance was used.
Results: We found three clusters. Cluster 1 (n = 45) had high levels of pain, fatigue, sleep problems, and mood
disturbances. Cluster 2 (n = 38) had intermediate degrees of depression and fatigue, but low pain and good sleep.
Cluster 3 (n = 42) had the lowest levels of pain, fatigue, and depression, but worse sleep quality than Cluster 2.
Conclusions: In adults with symptomatic OA, three distinct subgroups were identified. Although replication is
needed, many individuals with OA had symptoms other than joint pain and some (such as those in Cluster 1) may
have relatively stronger central nervous system (CNS) contributions to their symptoms. For such individuals,
therapies may need to include centrally-acting components in addition to traditional peripheral approaches.
Introduction
Osteoarthritis (OA) is the leading cause of disability in
US adults and its prevalence is expected to double by
2020 [1]. Historically, the “disease” of OA has been
viewed primarily as damage to the cartilage and bone. As
such, the magnitude of damage or inflammation of these
structures is often associated with higher symptom levels.
Population-based studies suggest otherwise; 30 to 50% of
individuals with moderate to severe radiographic changes
of OA are asymptomatic, and approximately 10% of indi-
viduals with moderate to severe knee pain have normal
radiographs [2,3]. Psychosocial factors do account for
some of this variance in pain and other symptoms, but
only modestly [4-6]. There also may be other bone, joint,
or physical changes associated with symptom severity
which are still not well-understood. The current failure
of peripheral damage, inflammation, or other factors to
explain the presence, absence, or severity of chronic pain
suggests the need to identify additional salient factors
that may be contributing to the experience of OA.
There is growing evidence in OA that there is a central
component to pain. Recent studies of animal models pro-
vide support for central sensitization of nociceptive path-
ways [7,8]. In addition, focus groups identified a subset of
patients with chronic, symptomatic knee OA who used
pain quality descriptors that were suggestive of neuro-
pathic pain [9]. There are several studies suggesting that
OA patients display diffuse hyperalgesia to mechanical or
heat stimuli (that is, suggestive of central nervous system
(CNS) mediation) [10-12]. Kosek demonstrated that indi-
viduals with hip OA had reduced descending analgesic
activity, which partially normalized following hip arthro-
plasty, suggesting the involvement of central factors influ-
encing the activity of peripheral nociceptive input [13].
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Gwilym and colleagues used both experimental pain test-
ing and more sophisticated functional neuroimaging
procedures to show evidence of augmented CNS proces-
sing of pain in 20 OA patients [14]. In a separate study,
this same group showed that atrophy of the thalamus was
seen at baseline on OA and improved following arthro-
plasty [15], again underscoring the role of the CNS in OA
pain. Finally, recent randomized controlled trials have
demonstrated that compounds that alter pain neurotrans-
mitters centrally, such as serotonin and norepinephrine,
(for example, duloxetine, tricyclics), are efficacious in OA
[16,17]. In aggregate, these studies do not imply that per-
ipheral factors are unimportant in OA; rather, peripheral
factors alone are insufficient to account for symptoms in
some or many individuals with OA. Whether or not CNS
augmentation plays a prominent role in OA pain is likely
to be tied to genetic predisposition, environmental stres-
sors, and the degree of illness burden a given person is
experiencing at the time [18-25]. Non-region-specific
symptoms accompanying pain, such as fatigue, cognitive
problems, sleep problems, and perturbations of mood, are
systemically-mediated symptoms that may index more
central involvement in the maintenance of illnesses, such
as pain [24,26,27]. These symptoms may be important to
target treatment in addition to pain. For instance, in a pre-
vious study with an OA sample, fatigue was actually more
related to functional disability than to pain [28]. To opti-
mize treatment, it may be necessary to better characterize
people with OA and determine if there are subsets of peo-
ple who have symptom presentations that may reflect dif-
ferent underlying pain mechanisms. Since OA treatment is
still largely focused on alleviating pain at the peripheral
site (for example, strength training to reduce knee joint
stress), it is particularly important to examine if there is a
subgroup of people with OA that has a symptom cluster
supporting a clinical presentation of centrally-mediated
pain. For those people, it may be important to focus on
treatment that is more commonly used in centrally-
mediated pain conditions, (such as behavioral treatments
and lifestyle interventions). Classification of people into
empirically-derived subgroups has been done in other
chronic pain conditions, such as fibromyalgia and low
back pain, based upon symptoms and psychosocial factors
and has successfully identified subgroups of patients with
distinct phenotypic characterization and with differential
response to treatment [29-31]. OA is similar to these
other chronic pain conditions in that many patients
experience multifocal pain, fatigue, sleep disturbances, and
mood disorders in addition to joint pain; however, no stu-
dies have examined if there are distinct subgroups of peo-
ple with OA who differ based on their symptomatology.
The purpose of this study was to identify specific sub-
groups of individuals who initially presented with sympto-
matic knee or hip OA. Subgroups would be based upon
levels of comorbid centrally-mediated symptomatology,
such as fatigue, sleep disturbance, mood, as well as other
symptoms, which we refer to as illness burden, known to
occur in other centrally-mediated pain states (for example,
irritable bowel syndrome, temporomandibular joint disor-
der, interstitial cystitis, and so on) [32]. We hypothesized
that one subgroup would appear to represent OA patients
who predominantly have joint pain, whereas other sub-
groups would have different symptom presentations that
support differential manifestations of CNS-mediated
symptomatology.
Materials and methods
Study design, participants, and setting
Our primary study was designed to examine the relation-
ship among pain, fatigue, and physical activity in older
adults with osteoarthritis. Potential participants were
recruited in various ways: through fliers (in clinics at the
University of Michigan Hospital System, at the Ann Arbor
VA Health Care System, and around several cities in
southeastern Michigan), newspaper advertisements, and
online through the University of Michigan’s clinical sub-
jects website. All individuals first signed an informed con-
sent document outlining the research project; this was
approved by the University of Michigan Institutional
Review Board and Ann Arbor Veteran’s Affairs Human
Subjects Review Board. The individuals underwent a com-
prehensive screening evaluation with a geriatrics nurse
practitioner who was trained by a rheumatologist to ascer-
tain the presence of clinical knee or hip OA using the
American College of Rheumatology (ACR) clinical criteria
[33,34] and to evaluate for the presence of comorbidities.
A total of 129 community-dwelling adults participated;
they were aged 65 years and older who initially self-
reported knee or hip OA.
Inclusion and exclusion criteria
To recruit people with painful OA, individuals were
included if they reported pain in a joint with OA on the
Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) scale (Likert version) of ≥ 4 with
at least two of the five items on the scale rated as moder-
ate pain or more [35]. This criterion was chosen because
our primary study involved an examination of the rela-
tionship of pain and fatigue to physical activity in a home
monitoring period, and we felt that this criterion would
allow us to capture variability in symptoms over that per-
iod. In addition, participants were included if they
reported experiencing fatigue symptoms at least a moder-
ate amount of the time (that is, three to four of the past
seven days) from one of two questions from the Center
for Epidemiologic Studies Depression Scale (CES-D; How
often in the past week: Did you feel like everything you
did was an effort? or Could you not get going?) [36].
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Participants also needed to have adequate cognition and
be able to see, hear and operate the accelerometer used
for pain reporting in the study. Individuals were excluded
if: 1) they reported other medical conditions that were
capable of causing fatigue (acute illnesses or exacerba-
tions of chronic illnesses, including common viral or bac-
terial infections, autoimmune diseases, fibromyalgia,
chronic fatigue syndrome, and any uncontrolled illness);
2) they were undergoing cancer treatment or had
received treatment for cancer in the previous 12 months;
3) they reported doctor-diagnosed obstructive sleep
apnea; 4) they presented with untreated anemia or thyr-
oid disorders per blood work; or 5) they were non-
ambulatory.
Measures
Pain
Individuals were provided with a wrist-worn accelerometer
(Actiwatch-Score, Philips Respironics-Mini-Mitter, Bend,
OR, USA) that measured physical activity patterns and
allowed ecological momentary assessment of pain five
times a day over a five-day home monitoring period (that
is, Monday through Friday). Based on our experience in
past studies, we chose sampling times that represented
each part of the day (wake-up, late morning to 11 am,
afternoon to 3 pm, evening to 7 pm, and bedtime). After
being prompted by the device’s audible alarm, participants
rated their pain on a scale of 0 to 10 ("No pain at all” to
“Pain as bad as I can imagine”). Pain ratings were then
summed over each day and averaged across all days to
derive an average pain rating. Because of our interest in
multi-focal pain mechanisms, we chose to include this
measure of pain rather than the WOMAC pain subscale
as we think it better captures global pain experience com-
pared to a disease-specific instrument.
Mood
Depressive symptomatology was assessed using the Center
of Epidemiologic Studies Depression Scale (CES-D) [36].
A score of 16 or greater on the CES-D has been associated
with clinically significant depressive symptoms [37].
Fatigue
The Brief Fatigue Inventory (BFI) was used to measure
total fatigue [38] calculated by averaging ratings on nine
items in which participants rate fatigue severity (“No
fatigue” to “As bad as you can imagine”) and interfer-
ence (“Does not interfere” to “Completely interferes”) in
daily life over the last week on a scale of 0 to 10 [38].
Illness burden
Illness burden is a concept that reflects the self-reported
symptom load experienced by an individual. For this
study, participants were asked whether they experienced
any of 41 different somatic symptoms with the sum
representing the “illness burden” variable in the analysis.
Examples of the types of symptoms include: stomach
pains, headaches, cognitive dysfunction, muscle weakness
or stiffness, restless sleep, and daytime sleepiness. Indivi-
dually these symptoms may represent various health pro-
blems associated with different body systems, but in
aggregate they may be viewed as the amount of burden a
given individual experiences stemming from centrally-
mediated somatic symptoms, such as fibromyalgia, irrita-
ble bowel syndrome, and chronic fatigue syndrome. In
other chronic pain conditions, greater endorsement of
such symptoms has been associated with greater central
pain and dysfunction status [39-41].
Sleep problems
Sleep problems were assessed using the Pittsburgh Sleep
Quality Index (PSQI) [42]. A total score is calculated
from seven subscales. A score of 5 or more indicates
greater difficulties with sleep.
Functional status
Functional status measures were not included in cluster-
ing, but were of interest to determine how different
symptom clusters were associated with function, included
both the short-form WOMAC physical disability scale
[43], and the objective “timed up and go test” [44], which
measures the time (in seconds) to get up from a chair,
walk 20 feet and return to the chair.
Statistical analysis
The variables selected for analytic clustering were chosen
based upon their known association with other central
pain conditions (for example, fibromyalgia and irritable
bowel syndrome) and by virtue of these variables being of
centrally-mediated origin rather than being symptoms of
peripheral or localized etiology. The symptoms chosen
for clustering included the following: pain, fatigue, sleep
problems, depressive symptoms, and somatic symptoms
(representing overall illness burden). Hierarchical
agglomerative cluster analysis utilized Ward’s method
with Squared Euclidean Distances in the proximities
matrix [45]. Visual inspection of the dendogram and an
evaluation of the dissimilarity measure were used to iden-
tify a three-cluster solution as being the best fit for these
data. Each variable within the clustering solution was
included in a subsequent multivariate analysis of variance
(MANOVA) comparing the three clusters in order to
determine the relative contribution of each variable
between clusters [46]. To facilitate grouping individuals
into clusters, a follow-up discriminant analysis was per-
formed. A constant and set of five coefficients (that is,
one for each variable in the analysis) were derived for
each cluster. These functions also facilitate accounting
for the variance attributable to each cluster and the
degree of separation between functions. Additional
analyses of variance (ANOVA) were used to identify
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concurrent clinical and demographic characteristics that
differed significantly depending upon subgroup member-
ship. All analyses were completed using PASW v18.
Results
Participant characteristics
Characteristics of the sample are shown in Table 1. There
were 172 people eligible for this analysis from 605 people
who underwent an initial phone screening for the study.
Of the 605, 27% were screened out due to not having
enough pain, 15% were screened out due to not having
enough fatigue, 12% were not aged 65 and older, 9% had
other conditions (for example, obstructive sleep apnea,
rheumatoid arthritis, inadequate cognition), and 2% had
a diagnosis of fibromyalgia. Complete data were available
on 129 of the 172 participants who were screened. The
missing data were from participants who decided not to
participate or were ineligible after full evaluation of the
screening results (such as due to not meeting the clinical
criteria for OA or abnormal results from blood work).
Therefore, these individuals did not complete the home
monitoring period required to obtain the average five-day
pain rating. Compared to the 129 participants (shown in
Table 1), the 43 participants had less pain on the
WOMAC scale (6.7 ± 3.7, P = .06) and less physical dis-
ability on the short-Form WOMAC scale (10.83/28 ±
4.26, P = .07). These participants had similar levels of
fatigue on the BFI (4.4 ± 1.9, P = .91) and depression on
the CES-D (12.2 ± 7.9, P = .97) compared to the sample
of 129 people. A total of 79 females and 50 males were
included in the current analysis with the majority of the
sample identifying themselves as either Caucasian (87%)
or African American (9%). Knee OA was the most com-
mon diagnosis (69%), followed by both knee and hip OA
(11%), and hip OA alone (20%). Scores on the WOMAC
indicated a mild-moderate pain experience among parti-
cipants (8.5 ± 3.2) with overall moderate levels of self-
reported physical dysfunction (12.30 ± 4.67). Average
pain severity for the sample was 3.06 (1.62) and average
fatigue severity was 3.77 (1.67).
Cluster analysis
Three clusters were identified as being the best fit for
these data. Significant separation of the variables contained
within the clustering solution was confirmed overall by
MANOVA (Wilks’ l = .148, F(10,236) = 37.69, P < .0001).
Subsequent univariate ANOVAs indicated significant dif-
ferences were observed between clusters for all variables
making up the clusters (all P ≤.0001). Post-hoc analyses
revealed significant differences between all variables and
all pairs of clusters except for pain severity where there
was not a significant difference between Clusters 2 and 3
(P = .09). Table 2 shows the characteristics of each cluster
by variable.
Cluster 1 comprised 36% of the sample (n = 45). This
group had the most pathological scores on all clustering
variables compared to the other two groups and was
characterized by the highest level of depressive symptoms
(17.3 which is above the clinical cut-point of 16), highest
fatigue and average pain (6.2 and 3.9/10 respectively), the
worst sleep, and the greatest illness burden (endorsing
30% of somatic symptoms that were queried).
Cluster 2 comprised 30% of the sample (n = 38). The
group was characterized by subclinical levels of depres-
sion and moderate fatigue, but had low pain and lower
levels of sleep problems (that is, 5.5). They had a mod-
erate illness burden (endorsing 25% of somatic
symptoms).
Cluster 3, comprised 34% of the sample (n = 42). This
group had clinically-relevant levels of sleep problems, but
mild levels of average pain (that is, 2.9/10). The group
had the lowest levels of fatigue and depression, and
markedly low levels of illness burden compared to the
two other clusters (that is, 13% of somatic symptoms
endorsed).
Table 1 Characteristics of the entire study sample
(n = 129, 79 female, 50 male)
Variable Mean (SD) Range
Age (years) 72.2 (9.8) 65 to 90
BMI (kg/m2) 30.5 (5.9) 21.5 to 49.9
Self-reported race Caucasian 112 (86.8%)
African American 12 (9.3%)
Asian 2 (1.6%)
More than one 1 (.8%)
Chose not to report 2 (1.6%)
Study joint knee 88 (68.2%)
hip 41 (31.7%)
% Veterans 26/120 (20.2%)
WOMAC pain 7.9 (3.4) 2 to 20
WOMAC stiffness 3.3 (1.7) 0 to 8
WOMAC disability 20.9 (10.3) 3 to 42
BFI total 4.5 (2.0) 0.25 to 8.75
Self-reported duration of pain (months) 132.1 (146.5) 0 to 708
Table 2 Cluster characteristicsa
Variable Cluster 1
(n = 45)
Cluster 2
(n = 38)
Cluster 3
(n = 42)
CES-D-depression 17.3 (7.1) 9.9 (5.0) 5.0 (3.4)
BFI-fatigue 6.2 (1.4) 4.0 (1.5) 3.0 (1.4)
PSQI 10.6 (3.6) 5.5 (2.1) 7.2 (2.9)
Average pain severity 3.9 (1.6) 2.3 (1.0) 2.9 (1.7)
No. of symptoms - Illness burden 12.2 (2.7) 10.4 (2.9) 5.3 (3.6)
aValues are the mean (SD). Multivariate ANOVA confirmed that each variable
was differentiated by the cluster solution (Wilks’ l = .148, F(10,236) = 37.69, P
< .0001) and univariate ANOVAs confirmed that each variable significantly
differentiated the clusters (all P < .0001).
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Clinical and demographic variables among subgroups
Age did not differ across clusters (mean = 72 years;
F(2,122) = .036, P = .97), and there was no significant
relationship between gender and cluster assignment
(c2 = 3.72, P = .16). Similarly, body mass index (BMI)
did not differ across clusters, being within the category
of obese (for example, 30 to 31) on average (F(2,122) =
1.02, P = .36). With regard to OA joints per the ACR
clinical criteria, we examined the clusters according to
whether they had knee OA alone or whether OA was in
both the hip and knee or in the hip joints alone. The
most prevalent group in all clusters had knee OA alone
(82% in Cluster 1, 64% in Cluster 2, and 63% in Cluster
3); however, location of OA joint was not significantly
different across clusters (c2 = 3.86; P = .15). Duration of
OA pain was not significantly different across the
groups and there was a large amount of variability
across people (F(2,122) = 2.58, P = .08); although Clus-
ter 2 had the longest pain duration at 177 months
(± 180) compared to Cluster 1 and Cluster 3 (124 ± 120
and 105 ± 126).
Differences in clusters were found in stiffness, physical
disability, and objective physical function. Stiffness on the
WOMAC scale was significantly different across groups
(F(2,121) = 5.95, P = .003), specifically between Cluster 1,
which had the highest level of stiffness (3.91 ± 1.60), and
Cluster 3, which had the lowest level (2.74 ± 1.70). Physi-
cal disability on the WOMAC disability scale was also
significantly different across clusters (F(2,122) = 16.18,
P = .0001). The significant difference in means from post-
hoc testing was 14.84 ± 4.50 in Cluster 1 compared to
Clusters 2 and 3 (9.84 ± 3.84 and 11.27 ± 3.98
respectively). On the timed up and go test, Cluster 1 had
a mean of 13.5 (± 8.9) which is a cut-off score denoting
fall risk (43) and was significantly different from Clusters
2 and 3 which were similar in their performance on this
test (10.5 ± 2.1 and 10.2 ± 2.3 respectively).
Discriminant functions
Two discriminant functions (that is, linear combinations
of the independent variables) were identified that signifi-
cantly differentiated the clusters accounting for 71% and
29% of the variance among them (Wilk’s Lambda for
Function 1: c2 = 168.28, P < .0001; and for Function 2:
c2 = 59.10, P < .0001). The first function was weighted
towards reported fatigue and number of endorsed somatic
symptoms, while the second function was weighted toward
reported pain and sleep quality. Figure 1 shows the multi-
variate group means (called the group centroids) for the
three clusters, the spread of the data in each cluster (repre-
sented by the different color circles), and the discriminant
functions. The distance between the centroids and amount
of overlap between the circles of each cluster shows how
the clusters are differentiated. The first discriminant func-
tion on the x axis separates Cluster 3 from Cluster 1,
while the second function on the y axis is needed to differ-
entiate Cluster 2 from the other two. As a second step, we
predicted group membership using a constant and coeffi-
cients for each of the predictor variables. These values
were applied in the same manner as for a regression
where the coefficient is multiplied by the individual value
and all values are summed. A value was generated for
each cluster and the highest value of the three represents
the cluster assignment. Table 3 shows the coefficients for
Function 1 
 Group Centroid
Fu
nc
tio
n 
2 
Cluster 1 
Cluster 2 
Cluster 3 
Figure 1 Illustration of required canonical discriminant functions to differentiate Clusters 1, 2 and 3. Two discriminant functions were
identified that significantly differentiated the clusters accounting for 71% and 29% of the variance among them (Wilk’s Lambda for Function 1:
c2 = 168.28, P < .0001; and for Function 2: c2 = 59.10, P < .0001).
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each cluster and illustrates an example of the predictive
process. Based on this method, we correctly classified
95.2% of participants in the sample into their empirically
derived clusters.
Discussion
In this study, we were interested in characterizing a sam-
ple of older adults with symptomatic knee and hip OA.
Three subgroups provided the best fit to our cluster analy-
tic model and each had different symptom presentations
that may be reflective of different degrees and types of
CNS-mediated symptomatology. There was a group (Clus-
ter 1; 36% of the sample) that appeared to have symptoms
reminiscent of fibromyalgia, including the highest ratings
on both pain and fatigue, as well as the worst ratings on
depressive symptoms and sleep. In addition, this group
also had the highest illness burden (that is, the number of
somatic symptoms endorsed which are common in other
centrally-mediated pain states, such as irritable bowel syn-
drome, temporomandibular joint disorder, and interstitial
cystitis), further supporting that a potential CNS contribu-
tion to symptoms.
Cluster 2 had intermediate levels of depressive symptoms
and modest levels of other somatic symptoms, suggesting
these individuals were suffering from mild depression.
Cluster 2 appears to be a group of relatively mixed central
influence, with perhaps mild depressive symptomatology,
but no significant evidence of sensory amplification symp-
toms that are more classically seen in fibromyalgia and
related conditions. Cluster 3 had low levels of all symptoms
except difficulties with sleep, where they had slightly greater
symptomatology than Cluster 2. Individuals within Cluster
3 may represent those individuals who have been tradition-
ally thought of as having OA confined to the joint. With
the exception of sleep problems, these individuals showed
minimal evidence of known central factors to be influen-
cing the overall condition.
Although our data appear to support the idea that differ-
ences in symptom presentation among clusters may be due
to differences in pain mechanisms, potential alternative
explanations were considered. For example, clusters may
have been differentiated due to differences in pain severity
rather than differences in pain mechanism. However,
because all groups have mild-moderate pain (2.3 to 3.9),
this seems unlikely. In addition, it could be argued that the
differences among clusters may be due to physical func-
tion. Specifically, Cluster 1, the group that was most symp-
tomatic, also had significantly worse scores on the
WOMAC physical disability scale and on the timed up and
go test than members of the other two clusters. This find-
ing is consistent with known associations between symp-
toms, depression, and function in chronic pain [47,48], and
reduced physical function could be a manifestation of hav-
ing a high symptom burden. However, a longitudinal study
would be needed to examine causality. In an additional
analysis, we further explored the relationship between pain
severity and physical function by examining correlations by
cluster. Correlations between pain severity and the physical
function variables (WOMAC physical disability and the
timed up and go test) were strongest and only statistically
significant for Cluster 3 (r = .55 and .32 respectively) sug-
gesting that this cluster, the one thought to be more of a
traditional OA group with joint pain and few other symp-
toms, has activity-related pain.
There is a growing body of literature that suggests pain
experienced in some individuals with OA could be due to
sensitization of both local and central pain pathways
[49,50]. Central pain disorders, such as fibromyalgia, are
characterized by widespread pain and the presence of
symptoms, such as fatigue, sleep problems, mood disor-
ders, and overall high illness burden, that were found in
participants in Cluster 1. This is interesting in light of the
fact we specifically excluded individuals with a diagnosis
of fibromyalgia from participating in the study, which was
further confirmed by ascertaining the presence of wide-
spread pain using a modification of the 1990 ACR criteria
[51]. Although we did not perform a tender-point exam,
we did ask individuals about the presence of pain in each
of the four body quadrants, as well as the axial skeleton,
and about tenderness to pressure at different points on the
body. Individuals needed to answer in the affirmative to
each of the widespread pain questions to be excluded
under the ‘fibromyalgia’ criterion. These findings suggest
that treatment approaches may need to be extended
beyond the joint in people with OA who present like those
in Cluster 1. Similar to another study [52], this study pro-
vides support for the idea that OA is likely a “mixed pain
state,” with individual variability in the relative balance of
peripheral (that is, nociceptive) and central elements of
pain. Although it is impossible to determine from our cur-
rent data, it is likely that some participants might have
undiagnosed fibromyalgia or widespread pain as defined
by the latest fibromyalgia diagnostic criteria [53]. This pos-
sibility bolsters the idea that there is a need for a broader
and more flexible approach to diagnosis and treatment of
symptoms in people who have OA. Potentially such indivi-
duals may benefit from treatments that target more
Table 3 Discriminative analysis of cluster characteristicsa
Variable Cluster 1 Cluster 2 Cluster 3
Constant -27.56 -13.30 -8.72
CES-D .49 .30 .09
BFI 2.89 1.93 1.23
Sleep disturbance 1.01 .40 .88
Pain .85 .17 1.20
Illness burden 1.04 1.05 .27
aValues are the coefficients for discriminant functions for each cluster. Values
in boldface indicate the variable loads highest for that particular cluster.
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centrally acting mechanisms and that are appropriate for
the management of fatigue, sleep, and depression, and
might be expected to preferentially respond to drugs such
as duloxetine, which has recently been shown to be effec-
tive in OA [16].
These findings should be considered preliminary given
that the clustering solution still requires replication in
another sample of OA patients. In addition, this study was
a first step into examining pain mechanisms in an OA
sample using symptom presentation as a grouping vari-
able. More sophisticated measurement, such as quantita-
tive sensory testing, is needed to more fully investigate the
pain mechanisms in these different subgroups. The struc-
tural severity of knee and hip OA is not known in this
study because the ACR clinical criteria was used and this
information would be useful in better understanding these
subgroups. Further, generalizability of the study findings
are limited to people with symptomatic knee or hip OA
and also may be limited by other characteristics of the
convenience sample we were able to access for this study.
Because a primary goal of the larger research project is to
examine fatigue in OA, we excluded people that did not
have enough fatigue; however, this was a relatively small
portion of the sample (15%). In addition, we included both
veterans and non-veterans in this study and this sample
comprised about 20% veterans. Veterans are more likely
than non-veterans to report chronic joint pain and activity
limitations [54] and a larger study would be needed to
examine differences between these two groups.
Conclusions
Among a group of community-dwelling older adults with
symptomatic knee or hip OA, we found evidence of three
statistically differentiated subgroups that were character-
ized by differing symptom presentations which may poten-
tially be due to different pain mechanisms. Although
further study and replication of the clusters are needed,
the heterogeneity of people with symptomatic OA in this
sample highlights the need to tailor treatment strategies
for symptom management.
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